Clinical Policy Title: Genetic testing for long QT syndrome (LQTS)
|
|
- Emil Little
- 6 years ago
- Views:
Transcription
1 Clinical Policy Title: Genetic testing for long QT syndrome (LQTS) Clinical Policy Number: Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 20, 2016 Next Review Date: July 2017 Policy contains: Familion testing. Long QT syndrome subtypes. RELATED POLICIES: CP# Molecular targeted therapy ABOUT THIS POLICY: AmeriHealth Caritas Pennsylvania has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Pennsylvania s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by AmeriHealth Caritas Pennsylvania when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Pennsylvania s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Pennsylvania s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Pennsylvania will update its clinical policies as necessary. AmeriHealth Caritas Pennsylvania s clinical policies are not guarantees of payment. Coverage Policy AmeriHealth Caritas Pennsylvania considers the use of genetic testing for long QT syndrome (LQTS), also known as Familion testing, to be clinically proven and therefore medically necessary when the following criteria are met: The individual has a close relative (first-, second- or third-degree) with a known LQTS mutation. The individual has a close relative (first-, second- or third-degree) diagnosed with LQTS by clinical means and whose genetic status is unavailable. The individual has palpitations, syncope and/or dizziness with a history of a close relative (first-, second-, or third-degree) who experienced a sudden cardiac death. The individual has a prolonged QT interval on resting electrocardiogram (a corrected QTc) of greater than 440 msec without an identifiable acquired or external cause for the QTc prolongation (i.e., bradycardia, electrolyte imbalance or certain medications/drugs) (QTc values of 0.44 sec are treated as suspicious, CSANZ 2011.) 1
2 The individual has signs and/or symptoms indicating a moderate-to-high pretest probability of LQTS using the Schwartz criteria (score of 2 3). Limitations All other uses of genetic testing for long QT syndrome/familion testing are not medically necessary. A negative genetic test in a clinically normal individual of a well-characterized family should eliminate the need for future testing (for the same individual), as genetic testing for a particular disease is usually performed once per lifetime. Note: The following CPT/HCPCS code is not listed in the Pennsylvania Medicaid fee schedule: S Genetic counseling, under physician supervision, each 15 minutes Alternative covered services Physical examination. Electric conductivity tests: electrocardiogram (ECG), echocardiography. Genetic counseling. Background Long QT syndrome (LQTS) is caused by mutations in a set of genes that code the protein subunits of cardiac ion channels. These ion channels are important for the electrical conductivity and signals of the heart. The electrical signals may be recorded by an electrocardiogram (ECG) and produce a characteristic waveform. The different components of the waveform are identified by the letters P, Q, R, S and T. The distinctive feature of LQTS is the lengthening of the Q T interval on an electrocardiogram (ECG). The Q T interval on the waveform represents the duration of the electrical activation and deactivation of the heart ventricles, which are the lower, main pumping chambers of the heart. With the advent of genetic testing, there is evidence of an overlap of specific genotypes that cause the characteristic T wave shapes. Normal Long QT LQTS genetic mutations may lead to an increase in the Q T Interval on an electrocardiogram. 2
3 In medical genetics, testing is done to diagnose individuals who possess chromosomal, genetic variations associated with a high risk of having or transmitting LQTS. The abnormal mutations and variations in DNA sequencing that cause LQTS are represented by abnormal allele configurations that are not found in the otherwise normal, healthy population. Genetic tests may be conducted for individuals who are asymptomatic or have a family member with this diagnosed genetic disorder. All first-degree relatives (i.e., siblings, parents and children) of an individual with an LQTS gene mutation have up to a 50 percent risk of harboring the same mutation. Typically, LQTS is inherited in an autosomal dominant pattern, in which a single mutation causes the disease. The genetic material (DNA) used for testing may be obtained from a blood sample or may be gathered by a mouth swab. Laboratories are able to offer multi-gene cardiomyopathy/cardiac panels that test many genes (may contain 50 or more) in an effort to diagnose several cardiac conditions at one time. The importance of identifying individuals for an inherited cardiac arrhythmia is highlighted by the potential lethality of these syndromes, mostly due to ventricular tachyarrhythmias. LQTS usually affects children or young adults, although it may occur in otherwise healthy individuals of various ages. Most people with LQTS are diagnosed either by family history, an episode of syncope, or by surviving a severe ventricular arrhythmia. For some unfortunate symptomatic individuals, the initial presentation of LQTS symptoms leads to sudden cardiac death. The goal of genetic testing for LQTS is to prevent sudden death through medical therapy, to counsel the individual and their family, and to assist with lifestyle changes (CSANZ, 2011). Literature suggests that LQTS may be responsible for as many as 3,000 unexpected deaths in children and young adults in the United States each year (Model, 2012). Younger individuals have a higher risk of unexpected sudden death than adults with a genetic cardiac disease. A family history of sudden death, possibly with genetic confirmation, may influence treatment decisions for those with suspected and ultimately confirmed LQTS. Because this disease is a primarily an electrical disorder, most individuals have no evidence of structural heart disease or LV dysfunction, making the long-term prognosis excellent if the arrhythmia is controlled. Treatment may involve beta blockers, permanent pacing, or left cervicothoracic sympathectomy (Tracy, et al, 2008). Practice guideline statements from the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and European Society of Cardiology (ESC) have noted an evolving role for genetic testing of LQTS in risk stratification and clinical decision-making (Zipes, et al., 2006). This stance pertaining to the use of risk stratification and data from genetic analysis becoming of increasing import to meaningful clinical decisionmaking was further addressed in the 2012 American College of Cardiology, American Heart Association Task Force, and European Society of Cardiology (ACCF/AHA/HRS) focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Both independent reviews and professional society guidelines agree that genetic testing should not be used alone in making recommendations for a prognosis for LQTS, though testing may be used to support clinical diagnosis and early detection of at-risk relatives (Ackerman, et al., 2011; Antzelevitch, et al.,2005; Priori and Cerrone, 2005). 3
4 Long QT syndrome subtypes Variant Gene Name Frequency Current Affected LQT1 KCNQ % K+, alpha subunit LQT2 KCNH % K+, alpha subunit LQT3 SCN5A 5 10% Na+, alpha subunit LQT4 ANK2 1 2% Na+, targeting protein LQT5 KCNE1 1% K+, beta subunit LQT6 KCNE2 Rare K+, subunit LQT7 KCNJ2 Rare K+, potassium channel LQT8 CACNA1C Rare Ca++, alpha 1C subunit LQT9 CAV3 Rare Na+, caveolin-3 protein Long QT syndrome subtypes Variant Gene Name Frequency Function LQT10 SCN4B Rare Na+, beta subunit LQT11 AKAP9 Rare K+, protein kinase LQT12 SNTA1 Rare Na+, α1-syntrophin LQT13 KCNJ5 Rare potassium channel Searches: AmeriHealth Caritas Pennsylvania searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality Guideline Clearinghouse and evidence-based practice centers. The Centers for Medicare & Medicaid Services. Searches were conducted in June 13, 2016 using the terms cardiac, genetic testing, Familion and long QT syndrome. We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings 4
5 The genetics of cardiac ion channelopathies are extremely varied. The number of genes that have been associated with causing long-qt syndrome has risen to 10, and there are hundreds of possible mutations in these genes that appear to be harmful. The Familion genetic test includes just 5 of the genes that are known to be associated with cardiac ion channelopathies and therefore, the number of symptomatic first-degree relatives of those with known LQTS mutations is high. The use of the Familion genetic test may potentially have clinical utility in patients with LQTS. For firstdegree relatives with known LQTS mutations in 1 of 5 genes included in the test, the Familion genetic test can confirm the presence of the familial mutation. A negative result is also instructive, as with the high analytical sensitivity and low probability of a sporadic mutation, a negative result would indicate a low probability of the patient having LQTS. Thus, use of the Familion genetic test in first-degree relatives of those with a known LQTS mutation may allow better use of prophylactic treatment for payers and avoidance of unnecessary restrictive activity for patients. Genetic tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA) Act of Premarketed approval from FDA is not required as long as the assay is performed in a laboratory facility that observes the CLIA regulations. The provider of the Familion genetic test has a current CLIA license. Policy updates: None. Summary of Clinical Evidence Citation Taggart NW, et. al. (2007) Content Key Points: Diagnostic miscues in congenital long-qt syndrome: BACKGROUND: Long-QT syndrome (LQTS) is a potentially lethal cardiac channelopathy that can be mistaken for palpitations, neurocardiogenic syncope and epilepsy. Because of increased physician and public awareness of warning signs suggestive of LQTS, there is the potential for LQTS to be overdiagnosed. The authors sought to determine the agreement between the dismissal diagnosis from an LQTS subspecialty clinic and the original referral diagnosis. METHODS AND RESULTS: Data from the medical record were compared with data from the outside evaluation for 176 consecutive patients (121 females, median age 16 years, average referral corrected QT interval [QTc] of 481 ms) referred with a diagnosis of LQTS. After evaluation at Mayo Clinic's LQTS Clinic, patients were categorized as having definite LQTS (D- LQTS), possible LQTS (P-LQTS), or no LQTS (No-LQTS). Seventy-three patients (41%) were categorized as No-LQTS, 56 (32%) as P-LQTS, and only 47 (27%) as D-LQTS. The yield of genetic testing among D-LQTS patients was 78% compared with 34% for P-LQTS and 0% among No-LQTS patients (P<0.0001). The average QTc was greater in either D-LQTS or P- LQTS than in No-LQTS (461 versus 424 ms, P<0.0001). Vasovagal syncope was more common among the No-LQTS subset (28%) than the P-LQTS/D-LQTS group (8%; P=0.04). Determinants for discordance (i.e., positive outside diagnosis versus No-LQTS) included overestimation of QTc, diagnosing LQTS on the basis of "borderline" QTc values and interpretation of a vasovagal fainting episode as an LQTS-precipitated cardiac event. CONCLUSIONS: Diagnostic concordance was present for less than one-third of the patients 5
6 who sought a second opinion. Two of every 5 patients referred with the diagnosis of LQTS departed without such a diagnosis. Miscalculation of the QTc, misinterpretation of the normal distribution of QTc values and misinterpretation of symptoms appear to be responsible for most of the diagnostic miscues. Moss et. al. (2007) Key Points: The effects of 77 different KCNQ1 mutations on phenotype in 600 patients from 101 families from the United States, Japan and the Netherlands were investigated: Mutations were classified according to their location in the KCNQ1, potassium channel position protein, i.e., N-terminus, transmembrane or C-terminus. Transmembrane mutations accounted for 66% of the mutations. In patients with transmembrane mutations, their QTc interval was longer, there was a higher incidence of cardiac events (syncope, aborted cardiac arrest or death) and the use of betablockers was more common. The QTc interval was also significantly longer in 19 patients who had 2 SCN5A mutations compared with those with a single mutation. In patients with KCNQ1 mutations that cause a > 50% increase in ion channel repolarizing current, the risk of cardiac events was approximately twice that of patients with mutations that cause a < 50% reduction in ion channel repolarizing current. The QTc was also significantly longer in patients with the worst impairment in ion channel function. Glossary Electrocardiogram (ECG, EKG) A test that records the electrical activity of the heart and displays the results on a visual graph. It is used to evaluate cardiac function, arrhythmias and the diagnosis of other cardiac disorders. Chromosome Within a single cell, a strand of amino acids that carries genetic information. Gene An integral part of a chromosome that determines an individual organism s hereditary physical characteristics. KCNQ1 Approved symbol. Approved name potassium voltage-gated channel subfamily Q member 1. Mutation Any change in the inherited genetic structure. Relatives, first-, second-, and third-degree An individual s close blood family members: First-degree relative Parents, full siblings or children. Second-degree relative Aunts, uncles, grandparents, grandchildren, nieces, nephews or half-siblings. Third-degree relative Great-grandparents, great aunts, great uncles or first cousins. Subtype One Type or component that is included in the long QT syndrome type. 6
7 References Professional society guidelines/other: Ackerman MJ, Priori SG, Williams S, Berul C, et al.. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm Aug;8(8): [Agency for Healthcare Research and Quality (ARHQ) Web site]. Available at:. Accessed June 13, 2016 Ackerman MJ, Priori SG, Williams, S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011; 13(8): American Academy of Pediatrics. Pediatric sudden cardiac arrest, section on cardiology and cardiac surgery. Pediatrics. March 26, American Heart Association (AHA) Website. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. May 15, Available at: Accessed June 13, American College of Cardiology, American Heart Association Task Force, European Society of Cardiology guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology committee for practice guidelines. J Am Coll Cardiol. 2006;48(5). Blue Cross Blue Shield Association (BCBSA), Technology Evaluation Center (TEC). Genetic testing for long QT syndrome TEC Assessments 2008;22(9). Chicago, IL. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 51: E. Epstein AE, et. al.,acc/aha/hrs 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities, J Am Coll Cardiol. 2008;51(21):e1-e62. doi: /j.jacc , Accessed June 13,
8 Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK Familial Sudden Cardiac Death Syndromes Statement Development Group. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace Aug; 12(8): Kapplinger JD, Tester DJ, Alders M, Benito B, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm Jan;7(1): Epub 2009 Oct 8. Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited Arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation Nov 13;116(20): Erratum in: Circulation Aug 19;118(8):e132. Skinner, J., et al. Guidelines for the diagnosis and management of familial long QT syndrome. The cardiac Society of Australia and New Zealand (CSANZ). August 10, Zipes DP, Camm AJ, Borggrefe M, Buxton AE, et al. American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation Sep 5;114(10):e Epub 2006 Aug 25. Peer-reviewed references: Ackerman MJ. Cardiac causes of sudden unexpected death in children and their relationship to seizures and syncope: genetic testing for cardiac electropathies. Semin Pediatr Neurol Mar;12(1):52-8. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation Feb 8;111(5): Epub 2005 Jan 17. Review. Erratum in: Circulation Jul 26;112(4):e74. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115(4):
9 Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-qt syndrome. Circulation 2012; 125(16): Baylor College of Medicine (BCM). John Welsh cardiovascular diagnostic laboratory. [BCM Web site]. 11/29/2011. Available at: Accessed June 13, Brenyo, A., Huang, D., Aktas. M. Congenital Long and Short QT Syndromes. Carfdiology, May 8, 2012;122: Brugada R, Campuzano O, Brugada P, Brugada J, Hong K. Brugada Syndrome Mar 31 [updated 2012 Jan 12]. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012; 9(6): Goldenberg, I., Horr, S., Moss, A., et al. Risk for life-threatening cardiac events in patients with genotypeconfirmed long-qt syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. January 4, 2011; 57(1):51-9. Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-qt syndrome: distinguishing pathogenic mutations from benign variants. Circulation. 2009; 120(18): Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009; 6: Modell SM, Lehmann MH. The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med Mar;8(3): Review. PubMed PMID: Accessed June 13, Modell, S., Bradley,D., and Lehmann, M. Genetic testing for long QT syndrome and the category of cardiac ion channelopathies. PLoS Curr. May 3, Moss AJ, Goldenberg I. Importance of Knowing the Genotype and the Specific Mutation When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol Aug;1(3):213-26; discussion 226. Review. PubMed PMID: ; PubMed Central PMCID: PMC
10 Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 lone-qt syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulations. 2007;115(19): Napolitano, C., Priori, S., Schwartz, P., et al. Genetic Testing in the Long QT Syndrome Development and Validation of an Efficient Approach to Genotyping in Clinical Practice. JAMA. 2005;294(23): National Center for Biotechnology Information (NCBI). Long QT syndrome 1: clinical laboratories. Available at: Accessed June 13, Priori SG, Cerrone M. Molecular genetics: is it making an impact in the management of inherited arrhythmogenic syndromes? Hellenic J Cardiol Mar-Apr;46(2):83-7. PubMed PMID: Refsgaard L, Holst AG, Sadjadieh G, et al. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet [Epub ahead of print]. Schwartz PJ, Moss AJ, Vincent GM et al. Diagnostic criteria for the long QT syndrome. An update. Circulation; 1993; 88(2): Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-qt syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1): Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini C. Prevalence of the congenital long-qt syndrome. Circulation Nov 3;120(18): Epub 2009 Oct 19. PubMed PMID: ; PubMed Central PMCID: PMC Sy RW, Chattha IS, Klein GJ, et al. Repolarization dynamics during exercise discriminate between LQT1 and LQT2 genotypes. J Cardiovasc Electrophysiol Nov;21(11): Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation Mar 8;123(9): Taggart NW 1, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in cogenital long-qt syndrome.2007 May 22; 115(20): Epub 2007 May 14. Transgenomic, Inc. FAMILION Comprehensive Genetic Tests for Cardiac Syndromes. [Transgenomic, Inc. Web site]. Available at: Accessed. June 13, Vetter VL, Clues or miscues? How to make the right interpretation and correctly diagnose long-qt syndrome. Circualtin. 2007:115(20):
11 Clinical trials Searched clinicaltrials.gov on June 13,2016 using termslong QT syndrome (LQTS), genetic testing Open Studies. 22 studies found, onerelevant. Massachusetts General Hospital.Boston, Massachusetts. Long QT syndrome (LQTS), and the subsequent fatal arrhythmia torsade de pointes (TdP), Published May 2015Updated March Accessed June 13, CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations MolecularPathologyProcedures.(L34519). Updated: 01/01/ Accessed June Commonly Submitted Codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comment Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2). Full sequence analysis. Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2). Known familial sequence variant. Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2). Duplication/Deletion variants. ICD-9 Code Description Comment Long QT syndrome Syncope and collapse Dizziness and giddiness Palpitations Nonspecific abnormal electrocardiogram (ECG) (EKG). V17.41 Family history of sudden cardiac death [SCD]. V18.9 Family history of genetic disease carrier. Symptoms of long QT syndrome. 11
12 V82.71 Screening for genetic disease carrier status. Genetic testing. V82.79 Other genetic screening. ICD-10 Code Description Comment I45.81 Long QT syndrome. R55 Syncope and collapse. Symptoms of syndrome. R42 Dizziness and giddiness. R00.2 Palpitations. R94.31 Abnormal electrocardiogram [ECG] [EKG]. Z82.41 Family history of sudden cardiac death. Z84.81 Family history of carrier of genetic disease. Z13.89 Encounter for screening for other disorder Z13.71 Encounter for nonprocreative screening for genetic disease carrier status. Genetic test screening. Z13.79 Encounter for other screening for genetic and chromosomal anomalies. HCPCS Level II S0265 Description Genetic counseling, under physician supervision, each 15 minutes. Comment 12
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS)
Clinical Policy Title: Genetic testing for long QT syndrome (LQTS) Clinical Policy Number: 04.01.02 Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 19, 2017
More informationGenetic Testing for Congenital Long QT Syndrome
Genetic Testing for Congenital Long QT Syndrome Policy Number: 2.04.43 Last Review: 11/2013 Origination: 6/2007 Next Review: 11/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationLong Q. Long QT Syndrome. A Guide for
Long Q Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United States
More informationStage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
More informationMedical Policy. Description/Scope. Rationale
Subject: Document #: Current Effective Date: 03/29/2017 Status: Reviewed Last Review Date: 02/02/2017 Description/Scope This document addresses genetic testing of cardiac ion channel mutations in persons
More informationLong QT. Long QT Syndrome. A Guide for Patients
Long QT Long QT Syndrome A Guide for Patients Long QT Syndrome What is long QT syndrome? Long QT syndrome (LQTS) is a condition that affects the ability of the heart to beat (contract) regularly and efficiently.
More informationThe Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes
The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes RHEA C. PIMENTEL, MD, FACC, FHRS UNIVERSITY OF KANSAS HOSPITAL MID AMERICA CARDIOLOGY AUGUST 19, 2012 Monogenic Arrhythmia Syndromes Mendelian
More informationProlonged QT Syndromes: Congenital and Acquired
Prolonged QT Syndromes: Congenital and Acquired April 30, 2014 Elizabeth S. Kaufman, MD I have no financial disclosures. MetroHealth Campus, Case Western Reserve University Prolonged QT Syndromes Congenital
More informationStrength and weakness of genetic testing in clinical routine.
Strength and weakness of genetic testing in clinical routine. Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular
More informationCongenital long QT syndrome of particularly malignant course connected with so far unknown mutation in the sodium channel SCN5A gene
CASE REPORT Cardiology Journal 2013, Vol. 20, No. 1, pp. 78 82 10.5603/CJ.2013.0012 Copyright 2013 Via Medica ISSN 1897 5593 Congenital long QT syndrome of particularly malignant course connected with
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Cardiac Ion Channelopathies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_cardiac_ion_channelopathies 10/2008 4/2018
More informationProtocol. Genetic Testing for Cardiac Ion Channelopathies
Protocol Genetic Testing for Cardiac Ion Channelopathies (20443) Medical Benefit Effective Date: 04/0/8 Next Review Date: /8 Preauthorization Yes Review Dates: 05/09, 05/0, 03/, 03/2, 03/3, 03/4, 03/5,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationGenetic Testing for Cardiac Ion Channelopathies
Genetic Testing for Cardiac Ion Channelopathies Policy Number: 2.04.43 Last Review: 11/2018 Origination: 6/2007 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationPGxHealth Reimbursement Services
PGxHealth Reimbursement Services Introduction The reimbursement environment for the FAMILION tests for inherited cardiac syndromes has improved significantly during the past three years. PGxHealth is devoting
More informationGenetics of Sudden Cardiac Death. Geoffrey Pitt Ion Channel Research Unit Duke University. Disclosures: Grant funding from Medtronic.
Genetics of Sudden Cardiac Death Geoffrey Pitt Ion Channel Research Unit Duke University Disclosures: Grant funding from Medtronic Duke U N I V E R S I T Y Sudden Cardiac Death High incidence 50-100 per
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Genetic Testing for Page 1 of 23 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Genetic Testing for Professional Institutional Original Effective Date: August
More informationName of Presenter: Marwan Refaat, MD
NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation
More informationMEDICAL POLICY POLICY TITLE T-WAVE ALTERNANS TESTING POLICY NUMBER MP
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY T-wave alternans is considered investigational as a technique
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Genetic Testing for Cardiac Ion Channelopathies Description Genetic testing is available for patients suspected of having
More informationPearls of the ESC/ERS Guidelines 2015 Channelopathies
Pearls of the ESC/ERS Guidelines 2015 Channelopathies Carina Blomstrom Lundqvist Dept Cardiology, Uppsala, Sweden Content 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
More informationHereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
More informationAsymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim
Asymptomatic Long QT Prof. Dr. Martin Borggrefe Mannheim QT interval Distribution of QTc intervals in large population-based studies Viskin S, Heart Rhythm 2009; 6: 711-715 QT interval Distribution of
More informationSyncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?
Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC
More informationBasics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD
Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD University of Pittsburgh Medical Center Pittsburgh, PA International Symposium of Inherited Arrhythmia Disorders and Hypertrophic
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationGenetic Testing for Cardiac Ion Channelopathies
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSection: Effective Date: Subsection: Original Policy Date: Subject: Page: Last Review Status/Date: Background
Genetic Testing for Cardiac Ion Last Review Status/Date: March 2014 Genetic Testing for Cardiac Ion Description Page: 1 of 22 Genetic testing is available for patients suspected of having cardiac ion channelopathies
More informationCONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT.
CONGENITAL LONG QT SYNDROME(CLQTS) ASSOCIATED WITH COMPLETE ATRIOVENTRICULAR BLOCK. A CASE REPORT. SAHA Annual Congress 2017. Samkelo Jiyana, Adele Greyling, Andile Nxele, ZM,Makrexeni,L.Pepeta. BACKGROUND
More informationCitation for published version (APA): Christiaans, I. (2010). Hypertrophic cardiomyopathy: towards an optimal strategy
UvA-DARE (Digital Academic Repository) Hypertrophic cardiomyopathy: towards an optimal strategy Christiaans, I. Link to publication Citation for published version (APA): Christiaans, I. (2010). Hypertrophic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Page 1 of 29 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Professional Institutional Original Effective Date: August 12,
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationWINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY
Learning Objectives to Disclose: To CRITIQUE the ICD and its role in the treatment of BrS, CPVT, and LQTS WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY Conflicts of Interest to Disclose: Consultant
More informationGenetic Testing for Heredity Cardiac Disease
Clinical Appropriateness Guidelines Genetic Testing for Heredity Cardiac Disease EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2064-1217 Table of Contents Scope... 3
More informationICD in a young patient with syncope
ICD in a young patient with syncope Konstantinos P. Letsas, MD, FESC Second Department of Cardiology Evangelismos General Hospital of Athens Athens, Greece Case presentation A 17-year-old apparently healthy
More informationPatient Resources: Cardiac Channelopathies
Patient Resources: Cardiac Channelopathies Overview of Cardiac Channelopathies: CPVT, Long QT Syndrome and Brugada Syndrome Heart muscle cells contract because of movement of certain molecules (called
More informationLeft cardiac sympathectomy to manage beta-blocker resistant LQT patients
Left cardiac sympathectomy to manage beta-blocker resistant LQT patients Lexin Wang, M.D., Ph.D. Introduction Congenital long QT syndrome (LQTS) is a disorder of prolonged cardiac repolarization, manifested
More informationLong QT Syndrome in Children in the Era of Implantable Defibrillators
Journal of the American College of Cardiology Vol. 50, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.042
More informationPreventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete
Preventing Sudden Death in Young Athletes Ronn E. Tanel, MD Director, Pediatric Arrhythmia Service UCSF Children s Hospital Associate Professor of Pediatrics UCSF School of Medicine Outline Sudden death
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationDescription. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015
Genetic Testing for Cardiac Ion Last Review Status/Date: December 2015 Genetic Testing for Cardiac Ion Description Page: 1 of 31 Genetic testing is available for patients suspected of having cardiac ion
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationΠαναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών
Διαστρωμάτωση κινδύνου για αιφνίδιο καρδιακό θάνατο σε ασθενείς που δεν συμπεριλαμβάνονται σε μεγάλες κλινικές μελέτες «Ασθενείς με ηλεκτρικά νοσήματα» Παναγιώτης Ιωαννίδης Διευθυντής Τμήματος Αρρυθμιών
More informationTailored therapy in long QT syndrome
Tailored therapy in long QT syndrome Dominic Abrams St. Bartholomew s & Great Ormond Street Hospitals London, UK Disclosures None Tailored therapy in long QTS Which patients should have tailored therapy...?...
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationProbability of diagnosing long QT syndrome in children and adolescents according to the criteria of the HRS/EHRA/APHRS expert consensus statement
European Heart Journal (2016) 37, 2490 2497 doi:10.1093/eurheartj/ehw072 CLINICAL RESEARCH Arrhythmia/electrophysiology Probability of diagnosing long QT syndrome in children and adolescents according
More informationRisk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals
Journal of the American College of Cardiology Vol. 57, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.038
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationFurther insights into inheritable arrhythmia syndromes: Focus on electrocardiograms Postema, P.G.
UvA-DARE (Digital Academic Repository) Further insights into inheritable arrhythmia syndromes: Focus on electrocardiograms Postema, P.G. Link to publication Citation for published version (APA): Postema,
More informationFANS Paediatric Pathway for Inherited Arrhythmias*
FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Predisposition to Inherited Hypertrophic File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_predisposition_to_inherited_hypertrophic_cardiomyopathy
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationVirtual Mentor American Medical Association Journal of Ethics August 2012, Volume 14, Number 8:
Virtual Mentor American Medical Association Journal of Ethics August 2012, Volume 14, Number 8: 604-609. ETHICS CASES Genetic Testing: Clinical and Personal Utility Commentary by Rachel A. Mills, MS, Susanne
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationCongenital long QT syndrome (LQTS) affects 1 in 2500
Original Article Left Cardiac Sympathetic Denervation in Long QT Syndrome Analysis of Therapeutic Nonresponders J. Martijn Bos, MD, PhD; Katy M. Bos, MS, RN, CNS; Jonathan N. Johnson, MD; Christopher Moir,
More informationMEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationGenetic Testing for Cardiac Ion Channelopathies. Description
Genetic Testing for Cardiac Ion Page: 1 of 30 Last Review Status/Date: March 2017 Genetic Testing for Cardiac Ion Description Genetic testing is available for patients suspected of having cardiac ion channelopathies
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationGenetic testing in Cardiomyopathies
Genetic testing in Cardiomyopathies Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione
More informationTopic: Outpatient Cardiac Telemetry Date of Origin: April Section: Medicine Last Reviewed Date: December 2014
Medical Policy Manual Topic: Outpatient Cardiac Telemetry Date of Origin: April 2010 Section: Medicine Last Reviewed Date: December 2014 Policy No: 135 Effective Date: February 1, 2014 IMPORTANT REMINDER
More informationWhen VF is the endpoint, wait and see is not always the best option.
Being free of symptoms does not necessarily mean free of arrhythmias. This Holter is from a asymptomatic 48 years old female with LQT2 When VF is the endpoint, wait and see is not always the best option.
More informationClinical Policy Title: Genetic testing for hereditary cardiomyopathy
Clinical Policy Title: Genetic testing for hereditary cardiomyopathy Clinical Policy Number: 02.01.24 Effective Date: October 1, 2016 Initial Review Date: August 17, 2016 Most Recent Review Date: August
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationCardiology Genetics Report Long QT Syndrome (LQTS) Panel
Patient Name: Test(s) Requested: The ordered test and the genes analyzed are Genes Evaluated (Disease): Result: Only mutations detected appear here KCNQ1 (LQT1 and Jervell and LangeNielsen syndrome), KCNH2
More informationManagement of Arrhythmia Syndromes in the Newborn and Very Young Child: Unique Risks & Barriers in this Age Population
Management of Arrhythmia Syndromes in the Newborn and Very Young Child: Unique Risks & Barriers in this Age Population Mitchell Cohen, MD FACC FHRS Co-Director Heart Center Chief of Pediatric Cardiology
More informationV4, V5 and V6 follow the 5 th intercostal space and are NOT horizontal as indicated in the image. Page 1 of 7
V4, V5 and V6 follow the 5 th intercostal space and are NOT horizontal as indicated in the image. Page 1 of 7 "Is it correct to place the electrodes under the female breasts?" Placement of electrodes directly
More informationClinical Policy: Microvolt T-Wave Alternans Testing Reference Number: CP.MP.212
Clinical Policy: Reference Number: CP.MP.212 Effective Date: 03/05 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationActive Cascade Screening in Primary Inherited Arrhythmia Syndromes
Journal of the American College of Cardiology Vol. 55, No. 23, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.12.063
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More informationΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ
ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ ΣΤΕΛΙΟΣ ΠΑΡΑΣΚΕΥΑÏΔΗΣ ΔΙΕΥΘΥΝΤΗΣ ΕΣΥ Α Καρδιολογική Κλινική ΑΠΘ, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη NO CONFLICT OF INTEREST Sudden Cardiac Death
More informationGenetic Testing for Hereditary Cardiomyopathies and Arrhythmias
Medical Coverage Policy Effective Date... 1/15/2018 Next Review Date...11/15/2018 Coverage Policy Number... 0517 Genetic Testing for Hereditary Cardiomyopathies and Arrhythmias Table of Contents Related
More informationJ. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam, the Netherlands
Inherited arrhythmia syndromes I: What you always wanted to know, but were afraid to ask: The basics of inherited arrhythmia syndromes and gene:cs J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam,
More information03/17/16, 03/16/17, 03/15/18 CATEGORY: Technology Assessment. Proprietary Information of Excellus Health Plan, Inc.
MEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationAdult Complexities of the Channelopathies
Adult Complexities of the Channelopathies Andrew Krahn MD FHRS Sauder Family and Heart and Stroke Foundation Chair in Cardiology Paul Brunes Chair in Heart Rhythm Disorders University of British Columbia
More informationThe Genetics and Prevention of Sudden Cardiac Death
The Genetics and Prevention of Sudden Cardiac Death Sudden cardiac death (SCD), a serious public health problem Every day, between 1,600 and 2,000 people die worldwide from genetically caused SCD. 1 SCD
More informationRhythm and Blues Drugs and QT Prolongation
Rhythm and Blues Drugs and QT Prolongation Dr Martin Quinn St Vincents University Hospital Irish Medication Safety Network conference Farmleigh 18 Oct 2013 Drugs and QT Prolongation Anti-psychotic, antidepressant,
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationClinical Policy Title: Genetic testing for hereditary cardiomyopathy
Clinical Policy Title: Genetic testing for hereditary cardiomyopathy Clinical Policy Number: 02.01.21 Effective Date: October 1, 2016 Initial Review Date: August 17, 2016 Most Recent Review Date: August
More informationWhen the rhythm of life is disturbed
Brugada Syndrome has the capacity to cause abnormal heart rhythms originating in the upper chambers of the heart When the rhythm of life is disturbed Cardiovascular disease continues to be a leading cause
More informationGenetic Testing for Hereditary Cardiomyopathies and Arrhythmias
Medical Coverage Policy Effective Date...11/15/2017 Next Review Date...11/15/2018 Coverage Policy Number... 0517 Genetic Testing for Hereditary Cardiomyopathies and Arrhythmias Table of Contents Related
More informationCHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT
CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT Inherited and Rare Cardiac Diseases Unit Heart Center for the Young and Athletes ONASSIS CARDIAC SURGERY CENTRE DIAGNOSIS ION CHANNEL DISEASE
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2018 Related Policies: None Genetic Testing for PTEN Hamartoma Tumor Syndrome Description The PTEN hamartoma tumor syndrome (PHTS) includes several syndromes
More informationRisk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed LongQT Syndrome and Normal-Range Corrected QT Intervals
Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed LongQT Syndrome and Normal-Range Corrected QT Intervals Goldenberg, Ilan; Horr, Samuel; Moss, Arthur J.; Lopes, Coeli M.; Barsheshet,
More informationCardiac implantable electronic devices (CIEDs) in children include pacemakers and implantable cardioverter defibrillators (ICDs).
Management of Children with Cardiac Devices Guideline originally developed by Leann Miles, APRN; Lindsey Pumphrey, RN; Srikant Das, MD, and the ANGELS Team. Last reviewed by Lindsey Pumphrey, RN, Srikant
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationGenetic Testing for Hereditary Cardiac Disease
Clinical Appropriateness Guidelines Genetic Testing for Hereditary Cardiac Disease EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2064-0319 Table of Contents Scope... 3
More informationBrugada Syndrome: An Update
Brugada Syndrome: An Update Osama Diab Associate professor of Cardiology Ain Shams university, Cairo, Egypt Updates Mechanism and Genetics Risk stratification Treatment 1 Brugada syndrome causes 4 12%
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More informationJ Wave Syndromes. Osama Diab Lecturer of Cardiology Ain Shams University
J Wave Syndromes Osama Diab Lecturer of Cardiology Ain Shams University J Wave Syndromes Group of electric disorders characterized by > 1 mm elevation of the J point or prominent J wave with or without
More informationExercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.
Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart. Hanne Rasmusen Consultant cardiologist, PhD Dept. of Cardiology Bispebjerg University Hospital
More informationProfessor Eric Schulze-Bahr
No CoI. Professor Eric Schulze-Bahr Institute for Genetics of Heart Diseases Department of Cardiology and Angiology University Hospital Münster / Germany ICD therapy in asymptomatic or borderline LQTS
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationClinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation
J Arrhythmia Vol 25 No 1 2009 Original Article Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation Seiji Takashio
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationCase studies in Channelopathies
Case studies in Channelopathies FABRICE CHOUTY, MD MEDICAL DIRECTOR HANNOVER-LIFE RE, PARIS (F) INTRODUCTION Thanks to the invasive electrophysiology and the progress of imaging techniques as well as the
More information